Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Sarcoma cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
IMMUNOSARC2Phase I - II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas | |
|---|---|
| Local Project Reference: | 17/0246 |
| Principal Investigator: | Dr. Sandra Strauss |
| Drug Class/ Treatment: | Nivolumab (PD-1 inhibiting IgG4 Monoclonal Antibody) and Sunitinib (RTK Inhibitor) Combination Treatment - Nivolumab IV and Sunitinib Oral Administration |
| Patient Population: | Advanced Soft Tissue and Bone Sarcomas |
| Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) | |
GSK 208467 NY-ESO (GSK 3377794)GSK3377794 safety & efficacy in NY-ESO positive solid tumour: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | |
|---|---|
| Local Project Reference: | 127000 |
| Principal Investigator: | Dr. Sandra Strauss |
| Drug Class/ Treatment: | GSL3377794 (T-Cell Immunotherapy) |
| Patient Population: | Advanced Synovial Sarcoma or Liposarcoma HLA-A2+ Participants with NY-ESO and/or LAGE-1a Positive Solid Tumours |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
FaR-RMSAn overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |
|---|---|
| Local Project Reference: | 120376 |
| Principal Investigator: | Dr. Maria Michelagnoli |
| Drug Class/ Treatment: | Trial of various Immunotherapy, Targeted Therapy Agents and Radiotherapy. |
| Patient Population: | Newly Diagnosed and Relapsed Rhabdomyosarcoma (RMS) Age >12 months and ≤25 years |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
SPEARHEAD-1A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |
|---|---|
| Local Project Reference: | 125255 |
| Principal Investigator: | Dr. Sandra Strauss |
| Drug Class/ Treatment: | ADP-A2M4 SPEAR™ T Cells - Genetically Modified T-Cells targeting MAGEA4 (Melanoma-Associated Antigen 4) |
| Patient Population: | Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Age 16 - 75 |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
